BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 23884059)

  • 1. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy.
    Taylor LE; Swan T; Matthews GV
    Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S118-24. PubMed ID: 23884059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.
    Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV
    Curr HIV/AIDS Rep; 2017 Jun; 14(3):110-121. PubMed ID: 28432579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
    Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?
    Panagiotoglou D; Krebs E; Min JE; Olding M; Ahamad K; Ti L; Montaner JSG; Nosyk B
    Int J Drug Policy; 2017 Sep; 47():169-176. PubMed ID: 28578865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV and viral hepatitis C coinfection in people who inject drugs: implications of new direct acting antivirals for hepatitis C virus treatment.
    Walsh N; Maher L
    Curr Opin HIV AIDS; 2012 Jul; 7(4):339-44. PubMed ID: 22498482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral hepatitis in persons living with HIV in the post-COVID era.
    Soriano V; Moreno-Torres V; Mendoza C; Corral O; Barreiro P
    AIDS Rev; 2023; 25(1):1-13. PubMed ID: 36952663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients.
    Rivero-Juarez A; Tellez F; Castaño-Carracedo M; Merino D; Espinosa N; Santos J; Macias J; Paniagua-García M; Zapata-Lopez A; Collado A; Gómez-Vidal MA; Perez-Stachowski J; Muñoz-Medina L; Fernandez-Fuertes E; Rivero A;
    HIV Med; 2019 Jul; 20(6):359-367. PubMed ID: 31006980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?
    Martin NK; Boerekamps A; Hill AM; Rijnders BJA
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25062. PubMed ID: 29633560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs.
    Socías ME; Ti L; Dong H; Shoveller J; Kerr T; Montaner J; Milloy MJ
    HIV Med; 2017 Oct; 18(9):647-654. PubMed ID: 28294492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection.
    Gobran ST; Ancuta P; Shoukry NH
    Front Immunol; 2021; 12():726419. PubMed ID: 34456931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.
    Roux P; Fugon L; Winnock M; Salmon-Céron D; Lacombe K; Sogni P; Spire B; Dabis F; Carrieri MP;
    Addiction; 2012 Jan; 107(1):152-9. PubMed ID: 21819472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).
    Mora M; Goodyear T; Marcellin F; Shoveller J; Di Beo V; Calzolaio C; Sogni P; Wittkop L; Zucman D; Poizot-Martin I; Lacombe K; Salmon-Céron D; Knight R; Carrieri P
    J Viral Hepat; 2020 Dec; 27(12):1462-1472. PubMed ID: 32810905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress of Hepatitis C elimination in Viennese people living with HIV after two decades of increasing cure rates.
    Chromy D; Bauer D; Simbrunner B; Jachs M; Hartl L; Schwabl P; Binter T; Steininger L; Schwarz C; Rieger A; Grabmeier-Pfistershammer K; Trauner M; Ferenci P; Peck-Radosavljevic M; Mandorfer M; Reiberger T
    Infect Dis (Lond); 2023 Mar; 55(3):189-198. PubMed ID: 36484317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.
    Grebely J; Bruneau J; Lazarus JV; Dalgard O; Bruggmann P; Treloar C; Hickman M; Hellard M; Roberts T; Crooks L; Midgard H; Larney S; Degenhardt L; Alho H; Byrne J; Dillon JF; Feld JJ; Foster G; Goldberg D; Lloyd AR; Reimer J; Robaeys G; Torrens M; Wright N; Maremmani I; Norton BL; Litwin AH; Dore GJ;
    Int J Drug Policy; 2017 Sep; 47():51-60. PubMed ID: 28683982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
    Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
    Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users.
    Hsu JT; Hsu PI; Shie CB; Chuah SK; Wu IT; Huang WW; Tang SY; Tsai KF; Kuo LF; Ghose S; Hsu JC; Shih CA
    Medicina (Kaunas); 2022 Mar; 58(3):. PubMed ID: 35334612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind.
    Grillon C; Krishtel PR; Mellouk O; Basenko A; Freeman J; Mendão L; Andrieux-Meyer I; Morin S
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25060. PubMed ID: 29633580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era.
    Falade-Nwulia O; Gicquelais RE; Astemborski J; McCormick SD; Kirk G; Sulkowski M; Thomas DL; Mehta SH
    Liver Int; 2020 Oct; 40(10):2407-2416. PubMed ID: 32770638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: a modeling analysis.
    Skaathun B; Borquez A; Rivero-Juarez A; Mehta SR; Tellez F; Castaño-Carracedo M; Merino D; Palacios R; Macías J; Rivero A; Martin NK
    BMC Infect Dis; 2020 Aug; 20(1):588. PubMed ID: 32770955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.